Clinical Trial Info: Ceftriaxone in ALS

Researchers conducting a clinical trial of the antibiotic ceftriaxone in amyotrophic lateral sclerosis (ALS) currently are recruiting participants at 57 locations across the United States and Canada.

About Clinical Trials

A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur. MDA has no ability to influence who is chosen to participate in a clinical trial. To learn more, see Understanding Clinical Trials and Being a Co-Adventurer, which is about neuromuscular disease clinical trials.

An informational webinar (Web-based seminar) about the trial will be held Wednesday, Feb. 9, 2011, at 2 p.m. EST, for anyone interested in learning more. It will be presented by neurologist Merit Cudkowicz, who is the principal investigator on the trial and director of the MDA/ALS Center at Massachusetts General Hospital in Boston.

Cudkowicz (pronounced “Suh-KO-vitch”) will describe the procedures used in the study, explain the scientific rationale behind the trial, and will be available to answer questions from webinar participants.

Ceftriaxone is an antibiotic that may confer neuroprotective benefits to the motor neurons (nerve cells) that die off in ALS. For more information, see Clinical Trial of Ceftriaxone in Subjects With ALS.

Those interested in viewing the webinar may click here to register. Early registration is recommended, as space is limited. After signing up, webinar participants will receive a confirmation e-mail with call-in instructions for the U.S. and Canada.

For more information, contact Sarah Titus, assistant project manager, at (617) 726-1398, or e-mail

1 461
Time Stamp: 
1 296 489 643
Node Type: